---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-071399"
form_type: "8-K"
ticker: "NKTX"
cik: "0001787400"
company_name: "Nkarta, Inc."
filed_at: "2025-05-14T23:59:59+00:00"
generated_at: "2026-05-21T09:39:02.760923+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Nkarta Q1 net loss $32M; restructures 34% workforce; NKX019 autoimmune data due H2 2025

## Summary
- Q1 2025 net loss $32M ($0.43/share); cash, equivalents & securities $351.9M.
- March 2025 restructuring cut 34% workforce; cash runway extended beyond 2029.
- Ntrust-1 expanded to include primary membranous nephropathy; lymphodepletion regimen updated.
- Initial NKX019 data across autoimmune indications expected H2 2025; both ISTs open.
- Robert Ortmann, M.D. appointed VP Clinical Development, joining May 15, 2025.

## SEC filing metadata
- accession: 0000950170-25-071399
- form_type: 8-K
- ticker: NKTX
- cik: 0001787400
- company_name: Nkarta, Inc.
- filed_at: 2025-05-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1787400/000095017025071399/0000950170-25-071399-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1787400/000095017025071399/nktx-20250514.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-071399
- JSON: https://secwatch.observer/filing/0000950170-25-071399.json
- Plain text: https://secwatch.observer/filing/0000950170-25-071399.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.